Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Evans

Showing results (581-590 of 621) with videos related to

Pageof 63
Sort By:
The Annals of Thoracic Surgery|August 23, 2015
Long-Term Venovenous Extracorporeal Membrane Oxygenation Support for Acute Respiratory Distress SyndromeZachary N Kon, Siamak Dahi, Charles F Evans, et al.
Nature Communications|August 29, 2024
Detection of distant relatedness in biobanks to identify undiagnosed cases of Mendelian disease as applied to Long QT syndromeMegan C Lancaster, Hung-Hsin Chen, M Benjamin Shoemaker, et al.
British Journal of Clinical Pharmacology|July 19, 2012
Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitorGretchen Bain, Christopher D King, Kevin Schaab, et al.
Biochemical and Biophysical Research Communications|December 3, 1999
Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14Q Liu, S S Pong, Z Zeng, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 19, 2016
Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver FibrosisGretchen Bain, Kristen E Shannon, Fei Huang, et al.
Bioorganic & Medicinal Chemistry Letters|November 17, 2009
5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitorNicholas Stock, Christopher Baccei, Gretchen Bain, et al.
Radiology|October 18, 2017
Breast Cancer Risk Associations with Digital Mammographic Density by Pixel Brightness Threshold and Mammographic SystemTuong L Nguyen, Yoon-Ho Choi, Ye K Aung, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 14, 2011
Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammationGretchen Bain, Daniel S Lorrain, Karin J Stebbins, et al.
American Journal of Respiratory and Critical Care Medicine|February 24, 2001
Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytesD J Figueroa, R M Breyer, S K Defoe, et al.
Journal of Medicinal Chemistry|September 11, 2009
5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103)John H Hutchinson, Yiwei Li, Jeannie M Arruda, et al.
Pageof 63

Showing results (581-590 of 621) with videos related to

Sort By:
Pageof 63
The Annals of Thoracic Surgery|August 23, 2015
Long-Term Venovenous Extracorporeal Membrane Oxygenation Support for Acute Respiratory Distress SyndromeZachary N Kon, Siamak Dahi, Charles F Evans, et al.
Nature Communications|August 29, 2024
Detection of distant relatedness in biobanks to identify undiagnosed cases of Mendelian disease as applied to Long QT syndromeMegan C Lancaster, Hung-Hsin Chen, M Benjamin Shoemaker, et al.
British Journal of Clinical Pharmacology|July 19, 2012
Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitorGretchen Bain, Christopher D King, Kevin Schaab, et al.
Biochemical and Biophysical Research Communications|December 3, 1999
Identification of urotensin II as the endogenous ligand for the orphan G-protein-coupled receptor GPR14Q Liu, S S Pong, Z Zeng, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 19, 2016
Selective Inhibition of Autotaxin Is Efficacious in Mouse Models of Liver FibrosisGretchen Bain, Kristen E Shannon, Fei Huang, et al.
Bioorganic & Medicinal Chemistry Letters|November 17, 2009
5-Lipoxygenase-activating protein inhibitors. Part 2: 3-{5-((S)-1-Acetyl-2,3-dihydro-1H-indol-2-ylmethoxy)-3-tert-butylsulfanyl-1-[4-(5-methoxy-pyrimidin-2-yl)-benzyl]-1H-indol-2-yl}-2,2-dimethyl-propionic acid (AM679)--a potent FLAP inhibitorNicholas Stock, Christopher Baccei, Gretchen Bain, et al.
Radiology|October 18, 2017
Breast Cancer Risk Associations with Digital Mammographic Density by Pixel Brightness Threshold and Mammographic SystemTuong L Nguyen, Yoon-Ho Choi, Ye K Aung, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 14, 2011
Pharmacology of AM211, a potent and selective prostaglandin D2 receptor type 2 antagonist that is active in animal models of allergic inflammationGretchen Bain, Daniel S Lorrain, Karin J Stebbins, et al.
American Journal of Respiratory and Critical Care Medicine|February 24, 2001
Expression of the cysteinyl leukotriene 1 receptor in normal human lung and peripheral blood leukocytesD J Figueroa, R M Breyer, S K Defoe, et al.
Journal of Medicinal Chemistry|September 11, 2009
5-lipoxygenase-activating protein inhibitors: development of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103)John H Hutchinson, Yiwei Li, Jeannie M Arruda, et al.
Pageof 63